WO2007070611A2 - Nutritional supplement containing long-chain polyunsaturated fatty acids - Google Patents
Nutritional supplement containing long-chain polyunsaturated fatty acids Download PDFInfo
- Publication number
- WO2007070611A2 WO2007070611A2 PCT/US2006/047642 US2006047642W WO2007070611A2 WO 2007070611 A2 WO2007070611 A2 WO 2007070611A2 US 2006047642 W US2006047642 W US 2006047642W WO 2007070611 A2 WO2007070611 A2 WO 2007070611A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nutritional supplement
- present
- kcal
- oil
- supplement
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 145
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 147
- 238000000034 method Methods 0.000 claims abstract description 97
- 150000002632 lipids Chemical class 0.000 claims abstract description 59
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 51
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 46
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 39
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 38
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 37
- 239000013589 supplement Substances 0.000 claims abstract description 37
- 235000016709 nutrition Nutrition 0.000 claims abstract description 25
- 230000035764 nutrition Effects 0.000 claims abstract description 14
- 235000004252 protein component Nutrition 0.000 claims abstract description 14
- 239000003921 oil Substances 0.000 claims description 44
- 235000019198 oils Nutrition 0.000 claims description 44
- 239000007788 liquid Substances 0.000 claims description 35
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 18
- 239000011707 mineral Substances 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 235000010469 Glycine max Nutrition 0.000 claims description 12
- 235000019486 Sunflower oil Nutrition 0.000 claims description 12
- 235000019519 canola oil Nutrition 0.000 claims description 12
- 239000000828 canola oil Substances 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 239000002600 sunflower oil Substances 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 11
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 10
- 235000005687 corn oil Nutrition 0.000 claims description 10
- 239000002285 corn oil Substances 0.000 claims description 10
- 229960004488 linolenic acid Drugs 0.000 claims description 9
- -1 xylo-oligosacchairde Polymers 0.000 claims description 9
- 208000017667 Chronic Disease Diseases 0.000 claims description 8
- 239000008122 artificial sweetener Substances 0.000 claims description 8
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 206010016165 failure to thrive Diseases 0.000 claims description 7
- 235000020778 linoleic acid Nutrition 0.000 claims description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 102000014171 Milk Proteins Human genes 0.000 claims description 6
- 108010011756 Milk Proteins Proteins 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 235000021239 milk protein Nutrition 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 235000020244 animal milk Nutrition 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 235000020256 human milk Nutrition 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 230000036737 immune function Effects 0.000 claims description 3
- 230000004630 mental health Effects 0.000 claims description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 230000037118 bone strength Effects 0.000 claims description 2
- 230000009084 cardiovascular function Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 235000000112 undernutrition Nutrition 0.000 claims 1
- 235000019197 fats Nutrition 0.000 abstract description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 132
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 67
- 229940090949 docosahexaenoic acid Drugs 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 239000004615 ingredient Substances 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 13
- 239000000835 fiber Substances 0.000 description 11
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 230000007407 health benefit Effects 0.000 description 10
- 229940033080 omega-6 fatty acid Drugs 0.000 description 10
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 9
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 108010009736 Protein Hydrolysates Proteins 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- 108010046377 Whey Proteins Proteins 0.000 description 8
- 102000007544 Whey Proteins Human genes 0.000 description 8
- 239000006014 omega-3 oil Substances 0.000 description 8
- 239000003531 protein hydrolysate Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 230000036996 cardiovascular health Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000199912 Crypthecodinium cohnii Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000199914 Dinophyceae Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 235000019498 Walnut oil Nutrition 0.000 description 3
- 235000021068 Western diet Nutrition 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000014510 cooky Nutrition 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 235000016768 molybdenum Nutrition 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 235000011649 selenium Nutrition 0.000 description 3
- 229940091258 selenium supplement Drugs 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 239000008170 walnut oil Substances 0.000 description 3
- 239000010497 wheat germ oil Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 2
- 244000205479 Bertholletia excelsa Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 241000273930 Brevoortia tyrannus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 241001070941 Castanea Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001422 FEMA 4092 Substances 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 241000233675 Thraustochytrium Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 108010033929 calcium caseinate Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940071162 caseinate Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 235000017802 other dietary supplement Nutrition 0.000 description 2
- 235000021400 peanut butter Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 235000007715 potassium iodide Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000008171 pumpkin seed oil Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001467606 Bacillariophyceae Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000196319 Chlorophyceae Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000206759 Haptophyceae Species 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229940002010 banana extract Drugs 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- IWIRHXNCFWGFJE-UHFFFAOYSA-L calcium;2,3-dihydroxypropyl phosphate Chemical compound [Ca+2].OCC(O)COP([O-])([O-])=O IWIRHXNCFWGFJE-UHFFFAOYSA-L 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940013712 pineapple extract Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a nutritional supplement, as a meal replacement or snack, or as a nutrient for subjects suffering from chronic illness, trauma, or failure to thrive that contains a unique lipid blend including a level of DHA supplementation and a low ⁇ -6: ⁇ -3 fatty acid ratio relative to the typical western diet in order to provide health benefits and/or to prevent adverse health consequences.
- DHA docosahexaenoic acid
- a nutritionally complete product supplemented with an appropriate level of DHA, in combination with an appropriate blend of dietary oils, may also help to address other growing health concerns.
- One of those concerns is increasing the level of ⁇ -6 fatty acids relative to ⁇ -3 fatty acids in the diet.
- Enfamil® Kindercal® (Mead Johnson, Evansville, IN), is intended to provide nutrition for children ages 1 to 10 years of age who require supplemental nutrition, a meal replacement, or a snack, or complete nutrition for chronic illness, injury, or failure to thrive.
- the currently marketed Kindercal® supplement has an ⁇ -6: ⁇ -3 ratio of about 5:1 , but does not contain DHA.
- Pediasure® (Ross Products Division, Abbott Laboratories, Columbus, OH) is designed for children 1 to
- W02003043445 to Cary, et a/. discloses a processed baby food useful for supplementing the diet of a child with precursors for the synthesis of arachidonic acid and DHA comprising a blend of linoleic acid and alpha-linolenic acid. Because this supplement only incorporates the precursors of LCPUFAs, it, therefore, lacks DHA.
- the described invention also specifies a relatively high ⁇ -6 fatty acid: ⁇ -3 fatty acid ratio of 7:1 to 12:1.
- W0200215719 to Fuchs, era/. discloses a composition for a nutritional supplement for a sick patient with a lipid source providing at least 18% of the total calories.
- the lipid source has an ⁇ -6: ⁇ -3 fatty acid ratio of approximately 1 :1 to 10:1.
- the supplement lacks DHA.
- U.S. Patent App. Nos. 20030000391 and 20030185941 to Highman, et ai disclose an organic nutritional beverage containing at least one of eicosapentaenoic acid (EPA) and DHA.
- EPA eicosapentaenoic acid
- DHA eicosapentaenoic acid
- Arachidonic and linolenic acids are also useful fatty acids in the beverage according to the invention.
- W02001047377 to Myhre discloses a nutritional liquid preparation containing oil mixed with an aqueous phase in order to improve freshness of the product.
- the nutritional liquid also has a high ratio of ⁇ -6: ⁇ -3 fatty acids.
- U.S. Patent No. 5,902,797 to Bell, et a/. discloses a nutritional supplement containing carbohydrate, protein, and fat, useful for an individual with suppressed appetite. DHA is not disclosed as a part of the supplement.
- DHA is not disclosed as a part of the supplement.
- nutritional compositions that provide health benefits and/or prevent adverse health consequences in children would also be desirable.
- compositions that are capable of providing the special nutritional requirements of children that suffer from chronic illness, injury, trauma, or failure to thrive would also be desirable.
- the invention is directed to a novel nutritional composition
- a protein component comprising a protein component; a carbohydrate component; and a fat or lipid component, which further comprises a source of DHA, wherein the supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- Another aspect of the invention relates to a method of providing nutrition to a subject comprising administering to the subject a nutritional supplement comprising a protein component; a carbohydrate component; and a fat or lipid component, which further comprises a source of DHA, wherein the supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the nutritional supplement is a nutritionally complete supplement.
- the nutritional supplement may be suitable as the exclusive source of caloric intake for the subject, or it may be optionally complemented with animal milk, human milk and/or other infant milks initially, and/or with solid foods or beverages later.
- the lipid blend of the present invention offers an improvement in the ⁇ -6 to ⁇ -3 fatty acid ratio in comparison to conventional nutritional supplements and current nutritionally complete supplements.
- the invention disclosed herein contains a unique lipid blend including a DHA-rich oil source, canola oil, high oleic sunflower oil, corn oil, soy oil and medium-chain triglyceride (MCT) oil that provides an appropriate level of DHA supplementation, and a low ⁇ -6: ⁇ -3 fatty acid ratio relative to the typical western diet in order to provide health benefits and/or to prevent adverse health consequences.
- a unique lipid blend including a DHA-rich oil source, canola oil, high oleic sunflower oil, corn oil, soy oil and medium-chain triglyceride (MCT) oil that provides an appropriate level of DHA supplementation, and a low ⁇ -6: ⁇ -3 fatty acid ratio relative to the typical western diet in order to provide health benefits and/or to prevent adverse health consequences.
- MCT medium-chain triglyceride
- the present invention provides an improved nutritional supplement that comprises protein, carbohydrate and lipid sources that include a meaningful level of DHA, yet has lower overall ratios of ⁇ -6 fatty acids to ⁇ -3 fatty acids.
- the present invention provides a nutritional supplement that provides health benefits and/or prevents adverse health consequences in children.
- the present invention provides methods and compositions that are capable of supplying the special nutritional requirements of children that suffer from chronic illness, injury, trauma, or failure to thrive.
- a pediatric nutritional supplement can be provided in a ready-to-use nutritionally complete form by admixing proteins, lipids, and carbohydrates into a composition in proportions that are appropriate for children.
- the present invention provides a nutritional supplement comprising a protein component, a carbohydrate component, and a lipid component that comprises a source of DHA, wherein the supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the nutritional supplement is a nutritionally complete pediatric supplement.
- “pediatric” and “children” refer to human subjects that are between the ages of 9 months and thirteen years old, and in some embodiments, more specifically to children between the ages of one and twelve years old. In a particular embodiment, the children are between the ages of one and ten years old.
- the term “nutritionally complete” refers to a nutritional supplement that may be used as the sole source of nutrition, which would supply to a subject essentially all the required daily amounts of vitamins, minerals and/or trace elements in combination with the proteins, carbohydrates and lipids.
- the present invention provides a benefit over conventional nutritional supplements in that the combination of the lipid blend with a meaningful level of DHA results in an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the ⁇ -6: ⁇ -3 ratio of such conventional products as PediaSure® is approximately 11:1.
- nutritional intake of lower overall ratios of ⁇ -6 to ⁇ -3 fatty acids may provide certain health benefits, including, but not limited to, improved immune function, cardiovascular improvement, prevention or treatment of asthma and other respiratory illnesses, bone strength, and various mental health benefits.
- PS phosphatidylserine
- PS is a phospholipid that is essential to the functioning of all the cells of the body, but is particularly concentrated in the brain. PS has been shown to have particular benefits in terms of mind and memory enhancement. It is believed that DHA can modulate PS levels in vivo and in vitro, as it has been shown that PS levels directly correlate with DHA content in neuronal cells.
- the nutritional supplement contains both lecithin and DHA.
- DHA increases the intracellular concentration of PS.
- the present invention may be especially helpful in improving brain function, memory, verbal ability, mood, sociability, stress, attention deficit disorders, and/or hyperactive disorders.
- the nutrient profile of the present invention may be, in one embodiment, designed primarily for the pediatric subject who cannot or will not consume adequate nutrition through traditional dietary sources.
- the nutritional supplement can be used as a pediatric nutritional supplement for children who are "picky-eaters", as a meal replacement
- the nutritional supplement described herein can be used as a nutritional supplement for convalescing children recovering from illness or surgery, those with limited appetite, anorexic children, bulimic children and for those children which have impaired ability to digest other sources of nutrition.
- the nutritional supplement may further comprise vitamins and minerals in amounts sufficient to supply the daily nutritional requirements of children between one and thirteen years old, and in some embodiments, the amounts may be selected according to FDA guidelines.
- the nutritional supplement may also contain other ingredients such as antioxidants, emulsifiers, stabilizers, preservatives, fiber, coloring agents, flavoring agents such as sweeteners, and other dietary supplements.
- the present invention also encompasses a method of providing nutrition to a subject comprising administering to the subject a nutritional supplement comprising a protein component, a carbohydrate component, and a lipid component that comprises a source of DHA, wherein the nutritional supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the subject is a pediatric subject.
- Suitable carbohydrates, lipids and proteins can vary widely and are well known to those skilled in the art of making pediatric nutritional supplements. Selection of one or more of the ingredients described herein can be a matter of formulation design or consumer and end-user preferences. For purposes of expediency, several ingredients that are suitable for use with methods and compositions of the present invention are described in further detail below. However, the present invention should not be construed as being limited to any one of the specific ingredients listed herein, since one of skill in the art will readily understand that many suitable ingredients other than the ones described herein could be used in addition to or in lieu thereof.
- One component of the methods and compositions of the present invention is one or more carbohydrates.
- carbohydrates As used herein, the term “carbohydrate” or “carbohydrates” refers to both simple carbohydrates
- the nutritional supplement of the present invention encompasses any source of carbohydrates that may be naturally- occurring, synthetic, or developed through the genetic manipulation of organisms, whether such new source is now known or later developed.
- sources of carbohydrates that are suitable for use with the methods and compositions of the present invention can include, but are not limited to, corn syrup solids; maltodextrin; sugars such as glucose, fructose, dextrose, lactose, galactose, saccharides, sucrose, and maltose; sugar alcohols such as sorbitol, mannitol and xylitol; syrups such as maltitol, corn syrup, rice syrup and high fructose corn syrup; and mixtures thereof.
- sugars such as glucose, fructose, dextrose, lactose, galactose, saccharides, sucrose, and maltose
- sugar alcohols such as sorbitol, mannitol and xylitol
- syrups such as maltitol, corn syrup, rice syrup and high fructose corn syrup; and mixtures thereof.
- the nutritional supplement described herein can also contain artificial sweeteners, e.g., sucralose, saccharine, cyclamates, aspartamine, aspartame, acesulfame K and/or sorbitol. Such artificial sweeteners can be desirable if the nutritional supplement is intended for an overweight subject, or a subject with type Il diabetes who is prone to hyperglycemia.
- artificial sweeteners e.g., sucralose, saccharine, cyclamates, aspartamine, aspartame, acesulfame K and/or sorbitol.
- Such artificial sweeteners can be desirable if the nutritional supplement is intended for an overweight subject, or a subject with type Il diabetes who is prone to hyperglycemia.
- the nutritional supplement of the present invention encompasses any source of artificial sweeteners that may be naturally-occurring, synthetic, or developed through the genetic manipulation of organisms, whether such new source is now known or later developed.
- Another component of the methods and compositions of the present invention is one or more proteins.
- proteins As used herein, the term “protein” or “proteins” refers to organic compounds that comprise amino acids joined by peptide bonds.
- the nutritional supplement of the present invention encompasses any source of protein that may be naturally-occurring, synthetic, or developed through the genetic manipulation of organisms, whether such new source is now known or later developed.
- sources of proteins that are suitable for use with the methods and compositions of the present invention can include, but are not limited to any suitable protein utilized in nutritional formulations including milk protein, milk protein concentrate, whey protein, whey protein concentrate, whey powder, lactalburnen, egg proteins (e.g., albumin), soy protein, soy protein isolate, rice protein, beef collagen, pea protein, potato protein, casein, caseinate (e.g., sodium caseinate, sodium calcium caseinate, calcium caseinate, potassium caseinate), animal (e.g., beef and fish), and mixtures thereof.
- Proteins that are suitable for use with the methods and compositions of the present invention can also include hydrolyzed proteins.
- hydrolyzed proteins or “protein hydrolysates” means protein which has been processed or treated in a manner intended to break one or more peptide (amide) bonds. Such hydrolyzed peptide fragments and free amino acids are more easily digested. The breakage of amide bonds may occur unintentionally or incidentally during manufacture, for example due to heating or shear.
- Suitable protein hydrolysates include, but are not limited to, soy protein hydrolysate, casein protein hydrolysate, whey protein hydrolysate, rice protein hydrolysate, potato protein hydrolysate, fish protein hydrolysate, egg albumen hydrolysate, gelatin protein hydrolysate, a combination of animal and vegetable protein hydrolysates; and mixtures thereof.
- the protein may also be provided in the form of free amino acids. Free amino acids may be added to the supplement in addition to the protein component.
- Suitable free amino acids include, but are not limited to, histidine, isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, carnitine, taurine and mixtures thereof.
- small amino acid peptides may be included as the protein of the present invention. Such small amino acid peptides may be naturally occurring or synthesized.
- the protein component comprises a milk protein concentrate, which is a blend of casein and whey protein. In some embodiments, the protein component comprises a blend of casein and whey, wherein the ratio of casein to whey is about 8:2.
- Another component of the methods and compositions of the present invention is one or more lipids. As used herein, the term "lipid" or
- lipids refers to fatty or oily organic compounds.
- the term “lipid” encompasses all fatty acid-type compounds. Lipids can be classified as either saturated, polyunsaturated, or monounsaturated.
- Sources of lipids that are suitable for use with the methods and compositions of the present invention include, but are not limited to, coconut oil, fish oil (e.g., menhaden oil, sardine oil), nut oils (e.g., hazelnut oil, walnut oil, brazil nut oil, chestnut oil, peanut oil), pumpkin seed oil, rice bran oil, sesame seed oil, soy oil, soya oil, corn oil, safflower oil, evening primrose oil, rapeseed oil, olive oil, flaxseed (linseed) oil, cottonseed oil, high oleic safflower oil, palm stearin, soy lecithin, macadamia oil, MCT oil
- the lipid component comprises a blend of several different types of lipids.
- the nutritional supplement may comprise a blend of at least one source of linoleic acid (an ⁇ -3 fatty acid) and at least one source of ⁇ - linolenic acid (an ⁇ -6 fatty acid). At least one source of DHA (an ⁇ -3 fatty acid) is also present in the nutritional supplement of the present invention.
- the types of lipids and the amount of lipids in the blend may be chosen so that the nutritional supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less, about 5:1 or less, about 4:1 or less, about 3:1 or less, about 2:1 or less, or about 1:1 or less.
- the nutritional supplement may simply have an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the nutritional supplement may have an ⁇ -6: ⁇ -3 fatty acid ratio somewhere in the range of between about 1 :1 and 6:1 , or between about 3:1 and about 6:1.
- the nutritional supplement may have an ⁇ -6: ⁇ -3 fatty acid ratio within the range of between about 5:1 and about 6:1.
- the nutritional supplement may have an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1.
- the nutritional supplement may have an ⁇ - 6: ⁇ -3 fatty acid ratio of about 5:1.
- the nutritional supplement comprises a blend of 1 ) at least one source of the ⁇ -3 fatty acid, linoleic acid, 2) at least one source of the ⁇ -6 fatty acid, ⁇ - linolenic acid, and 3) at least one source of the ⁇ -3 fatty acid, DHA, wherein the ratio of the amount of total ⁇ -6 fatty acid to the amount of total ⁇ -3 fatty acid is about 6:1 or less.
- Suitable sources of oils rich in linoleic acid include, but are not limited to, sunflower oil, cottonseed oil, walnut oil, soybean oil, whole grain oil, wheat germ oil, chestnut oil, pumpkin seed oil, sesame oil, brazilnut oil, peanut oil, safflower oil, com oil, animal fat, and mixtures thereof.
- Suitable sources of oils rich in ⁇ -linolenic acid include, but are not limited to, linseed oil (or flaxseed oil), canola oil, soybean oil, walnut oil, wheat germ oil, and mixtures thereof.
- Suitable sources of DHA include, but are not limited to, dairy products like eggs (e.g., egg yolk oil) and butterfat; marine or fish oils, such as cod, salmon, menhaden, sardine, tuna and many other fish; brain lipids, animal fats (e.g., beef and chicken fat), animal organs, lard, tallow; and microbial oils such as fungal and algal oils described in detail in U.S. Patent Nos. 5,347,657; 5,550,156; and 5,658,767.
- DHA that is suitable for use with the present invention may be isolated from any single-celled organism that contains a significant amount of DHA. This would include various oleaginous fungi, various algae (especially members of the class Dinophyceae, Bacillariophyceae,
- Chlorophyceae Prymnesiophyceae and Euglenophyceae
- organisms of uncertain taxonomic status such as Thraustochytrium or Schizochytrium.
- Suitable processes for producing DHA-containing lipids from Thraustochytrium or Schizochytrium are provided in U.S. Pat. No. 5,130,242, which is incorporated herein in its entirety by reference thereto.
- Algal oils such as those from dinoflagellates of the class Dinophyceae, notably Crypthecodinium cohnii may be suitable sources of DHA (including DHASCOTM and DHASCO-STM), as taught in U.S. Patent Nos. 5,397,591 ; 5,407,957; 5,492,938; and 5,711 ,983, all of which are incorporated herein in their entireties by reference thereto.
- DHA including DHASCOTM and DHASCO-STM
- Crypthecodinium cohnii has been manipulated to produce very high levels of DHA.
- This organism may be cultivated at a large scale and the biomass can be used for the production of a DHA-containing oil.
- Suitable processes for producing a DHA-containing biomass from C. cohnii are provided in U.S. Pat. Nos. 5,397,591 and 5,492,938, each of which is incorporated herein in its entirety by reference thereto.
- the nutritional supplement of the present invention also encompasses any new source of DHA that may be developed synthetically or through genetic manipulation of organisms, such as vegetables and/or oil bearing plants.
- the nutritional supplement comprises a blend of sources of lipids comprising two or more of canola oil, soybean oil, high oleic sunflower (HoSun) oil, medium chain triglyceride (MCT) oil, corn oil, and in certain aspects of the present invention, the blend comprises a blend of all five of these oils.
- the blend of sources of lipids comprises a blend of canola oil, soybean oil, high oleic sunflower oil, medium chain triglyceride (MCT) oil, and corn oil; and in combination with DHA oil, provides the nutritional supplement with an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- the nutritional supplement may also contain other ingredients in addition to the carbohydrates, proteins, lipids, and DHA described previously, such as one or more vitamins, minerals, antioxidants, fibers, flavoring agents, coloring agents, preservatives, emulsifiers, and other dietary supplements, and mixtures thereof.
- compositions of the present invention may optionally include one or more of the following vitamins or derivatives thereof, including, but not limited to, biotin, vitamin B-i, thiamin, thiamin pyrophosphate, vitamin B 2 , riboflavin, flavin mononucleoride, flavin adenine dinucleotide, pyridoxine hydrochloride, thiamin mononitrate, folic acid, vitamin B3, niacin, nicotinic acid, nicotinamide, niacinamide, nicotinamide adenine dinucleotide, tryptophan, biotin, pantothenic acid, vitamin B 6 , vitamin Bi 2 , cobalamin, methylcobalamin, deoxyadenosylcobalamin, cyanocobalamin, calcium pantothenate, pantothenic acid, vitamin C, ascorbic acid, vitamin A, retinol, retinal, retinoi
- the methods and compositions of the present invention may optionally include one or more of the following minerals or derivatives thereof, including, but not limited to, phosphorus, potassium, sulfur, sodium, docusate sodium, chloride, manganese, magnesium, magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium sulfate, copper, cupric sulfate, iodide, boron, zinc, zinc oxide, chromium, molybdenum, iron, carbonyl iron, ferric iron, ferrous fumarate, polysaccharide iron, fluoride, selenium, molybdenum, calcium phosphate or acetate, potassium phosphate, magnesium sulfate or oxide, sodium chloride, potassium chloride or acetate, ferric orthophosphate, alpha- tocopheryl acetate, zinc sulfate or oxide, copper gluconate, chromium chloride or picolonate, potassium iodide, sodium selenate, sodium moly
- Non- limiting exemplary derivatives of mineral compounds include salts, alkaline salts, esters and chelates of any mineral compound.
- the minerals can be added in the form of salts such as calcium phosphate, calcium glycerol phosphate, sodium citrate, potassium chloride, potassium phosphate, magnesium phosphate, ferrous sulfate, zinc sulfate, cupric sulfate, manganese sulfate, and sodium selenite. Additional vitamins and minerals can be added as known within the art.
- compositions of the present invention may optionally include one or more of the following flavoring agents, including, but not limited to, flavored extracts, volatile oils, cocoa or chocolate flavorings, peanut butter flavoring, cookie crumbs, vanilla or any commercially available flavoring.
- flavoring agents including, but not limited to, flavored extracts, volatile oils, cocoa or chocolate flavorings, peanut butter flavoring, cookie crumbs, vanilla or any commercially available flavoring.
- useful flavorings include, but are not limited to, pure anise extract, imitation banana extract, imitation cherry extract, chocolate extract, pure lemon extract, pure orange extract, pure peppermint extract, imitation pineapple extract, imitation rum extract, imitation strawberry extract, or vanilla extract; or volatile oils, such as balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, or peppermint oil; peanut butter, chocolate flavoring, vanilla cookie crumb, butterscotch, toffee, and mixtures thereof.
- the amounts of flavoring agent can vary greatly depending upon the flavoring agent used. The type and amount of flavoring agent can be selected as is known in the art.
- the methods and compositions of the present invention may optionally include one or more emulsifiers that may be added for stability of the final product.
- suitable emulsifiers include, but are not limited to, lecithin (e.g., from egg or soy), and/or mono- and di-glycerides, and mixtures thereof.
- Other emulsifiers are readily apparent to the skilled artisan and selection of suitable emulsifier(s) will depend, in part, upon the formulation and final product.
- the methods and compositions of the present invention may optionally include one or more preservatives that may also be added to the nutritional supplement to extend product shelf life. Suitable preservatives include, but are not limited to, potassium sorbate, sodium sorbate, potassium benzoate, sodium benzoate, and calcium disodium EDTA, and mixtures thereof.
- the methods and compositions of the present invention may optionally include one or more sources of fiber, including, but not limited to, soy fiber, pea hull fiber, soy hull fiber, gum acacia, and mixtures thereof.
- the nutritional supplement of the present invention encompasses any source of fibers that may be naturally-occurring, synthetic, or developed through the genetic manipulation of organisms, whether such new source is now known or later developed.
- the methods and compositions of the present invention may optionally include one or more stabilizers.
- Suitable stabilizers for use in the methods and compositions of the present invention include, but are not limited to, gum arabic, gum ghatti, gum karaya, gum tragacanth, agar, furcellaran, guar gum, gellan gum, locust bean gum, pectin, low methoxyl pectin, gelatin, microcrystalline cellulose, CMC (sodium carboxymethylcellulose), methylcellulose hydroxypropyl methyl cellulose, hydroxypropyl cellulose, DATEM (diacetyl tartaric acid esters of mono- and diglycerides), dextran, carrageenans, and mixtures thereof.
- carbohydrates are present in the nutritional supplements of the present invention in an amount that can range from about 1 gram (g)/100 kilocalories (kcal) to about 50 g/100 kcal. In other embodiments, the amount of carbohydrate can range from about 5 g/100 kcal to about 25 g/100 kcal. In still other embodiments, the amount of carbohydrate can range from about 10 g/100 kcal to about 15 g/100 kcal.
- the amount of carbohydrate that is present in the nutritional supplements of the present invention can be about 12.8 g/100 kcal.
- Proteins are present in the nutritional supplements of the present invention in an amount that can range from about 0.1 g/100 kcal to about 20 g/100 kcal. In other embodiments, the amount of protein can range from about 0.5 g/100 kcal to about 10 g/100 kcal. In still other embodiments, the amount of protein can range from about 1 g/100 kcal to about 5 g/100 kcal. In some embodiments, the amount of protein that is present in the nutritional supplements of the present invention can be about 2.8 g/ 100 kcal.
- Lipids are present in the nutritional supplements of the present invention in an amount that can range from about 0.1 g/100 kcal to about 50 g/100 kcal. In other embodiments, the amount of lipid can range from about 1 g/100 kcal to about 20 g/100 kcal. In still other embodiments, the amount of lipid can range from about 2 g/100 kcal to about 10 g/100 kcal. In some embodiments, the amount of lipid that is present in the nutritional supplements of the present invention can be about 4.2 g/ 100 kcal.
- the amount of linoleic acid present in the nutritional supplements of the present invention can range from about 0.1 g/100 kcal to about 20 g/100 kcal. In other embodiments, the amount of linoleic acid can range from about 0.5 g/100 kcal to about 5 g/100 kcal or the amount can range from about 0.75 g/100 kcal to about 2 g/100 kcal. In still other embodiments, the amount of linoleic acid can be about 1 g/100 kcal.
- the amount of ⁇ -linolenic acid present in the nutritional supplements of the present invention can range from about 0.01 g/100 kcal to about 10 g/100 kcal. In other embodiments, the amount of ⁇ -linolenic acid can range from about 0.05 g/100 kcal to about 1 g/100 kcal or the amount can range from about 0.1 g/100 kcal to about 0.2 g/100 kcal. In still other embodiments, the amount of ⁇ -linolenic acid can be about 0.16 g/100 kcal.
- the amount of DHA present in the nutritional supplements of the present invention can range from 0.1 milligram (mg)/100 kcal to about 1 g/100 kcal. In other embodiments, the amount of DHA can range from about 1 mg/100 kcal to about 200 mg/100 kcal or the amount can range from about 5 mg/100 kcal to about 50 mg/100 kcal. In still other embodiments, the amount of DHA can range from about 7.5 mg/100 kcal to about 25 mg/100 kcal. In certain aspects of the present invention, the amount of DHA can be about 17 mg/100 kcal.
- the amount of DHA present in the nutritional supplements of the present invention may vary within a wide range based on the caloric content of the supplement.
- the amount of DHA present in the nutritional supplements and methods described herein may comprise a meaningful level of DHA.
- the terms "meaningful level” or “meaningful levels” refer to an amount of DHA that can provide a health benefit to at least one of the subjects described herein no matter how slight the benefit.
- Such health benefits may include, but are not limited to, increased dietary intakes, enhanced physical growth, improved brain and/or ocular development, improved immune health ad function, and improved cardiovascular health and function.
- the nutritional supplement may comprise a blend of sources of lipids comprising in % w/w of the total lipid component of between about 10% and about 50 % canola oil, between about 5% and about 40% soybean oil, between about 5% and about 40% high oleic sunflower oil, between about 5% and about 40% medium chain triglyceride (MCT) oil, between about 1 % and about
- the aforementioned nutritional supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- weight percentages and the acronym “wt. %” or “w/w” as used herein refer to weight percentages based on the total weight of either one component of the nutritional supplement, which will be specified, or it will based on the nutritional supplement in its final form with all ingredients added.
- the nutritional supplement of the present invention may comprise a blend of sources of lipids comprising in % w/w of the total lipid component of about 29.3% canola oil, about 20.7% soy oil, about 20.5% high oleic sunflower oil, about 19.8% medium chain triglyceride oil, about 8.8% corn oil, and about 0.9% of a source of DHA.
- the aforementioned nutritional supplement has an ⁇ -6: ⁇ -3 fatty acid ratio of about 6:1 or less.
- vitamin A when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 1 mcg/100 kcal to about 500 mcg/100 kcal. More advantageously, the vitamin A can be present in the methods and/or compositions of the present invention in an amount of about 70 mcg/100 kcal.
- vitamin D When vitamin D is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 100 mcg/100 kcal. More advantageously, the vitamin D can be present in the methods and/or compositions of the present invention in an amount of about 1.24 mcg/100 kcal. [00079] When vitamin E is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg to about 100 mg. More advantageously, the vitamin E can be present in the methods and/or compositions of the present invention in an amount of about 2.36 mg.
- vitamin K is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 100 mcg/100 kcal. More advantageously, the vitamin K can be present in the methods and/or compositions of the present invention in an amount of about 5.4 mcg/100 kcal.
- vitamin Bi is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mg/100 kcal to about 10 mg/100 kcal. More advantageously, the vitamin Bi can be present in the methods and/or compositions of the present invention in an amount of about 0.16 mg/100 kcal.
- vitamin B2 When vitamin B2 is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mg/100 kcal to about 10 mg/100 kcal. More advantageously, the vitamin B2 can be present in the methods and/or compositions of the present invention in an amount of about 0.2 mg/100 kcal. [00083] When vitamin Be is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mg/100 kcal to about 10 mg/100 kcal. More advantageously, the vitamin B 6 can be present in the methods and/or compositions of the present invention in an amount of about 0.2 mg/100 kcal.
- vitamin B12 is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mcg/100 kcal to about 10 mcg/100 kcal. More advantageously, the vitamin B 12 can be present in the methods and/or compositions of the present invention in an amount of about 0.56 mcg/100 kcal.
- niacin is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 100 mg/100 kcal. More advantageously, the niacin can be present in the methods and/or compositions of the present invention in an amount of about 2.45 mg/100 kcal.
- folic acid When folic acid is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 500 mcg/100 kcal. More advantageously, the folic acid can be present in the methods and/or compositions of the present invention in an amount of about 20 mcg/100 kcal.
- pantothenic acid When pantothenic acid is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 100 mg/100 kcal. More advantageously, the pantothenic acid can be present in the methods and/or compositions of the present invention in an amount of about 1.24 mg/100 kcal.
- biotin when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 100 mcg/100 kcal. More advantageously, the biotin can be present in the methods and/or compositions of the present invention in an amount of about 15.2 mcg/100 kcal.
- vitamin C when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mg/100 kcal to about 1 g/100 kcal. More advantageously, the vitamin C can be present in the methods and/or compositions of the present invention in an amount of about 23.2 mg/100 kcal.
- choline When choline is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the choline can be present in the methods and/or compositions of the present invention in an amount of about 25.2 mg/100 kcal.
- inositol When inositol is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the inositol can be present in the methods and/or compositions of the present invention in an amount of about 6.8 mg/100 kcal.
- taurine When taurine is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the taurine can be present in the methods and/or compositions of the present invention in an amount of about 6 mg/100 kcal.
- carnitine When carnitine is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the carnitine can be present in the methods and/or compositions of the present invention in an amount of about 6 mg/100 kcal.
- calcium is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 1 g/100 kcal. More advantageously, the calcium can be present in the methods and/or compositions of the present invention in an amount of about 96 mg/100 kcal.
- phosphorus is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 1 g/100 kcal. More advantageously, the phosphorus can be present in the methods and/or compositions of the present invention in an amount of about 80 r ⁇ g/100 kcal.
- magnesium when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the magnesium can be present in the methods and/or compositions of the present invention in an amount of about 14 mg/100 kcal.
- iron when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 100 mg/100 kcal. More advantageously, the iron can be present in the methods and/or compositions of the present invention in an amount of about 1 mg/100 kcal.
- zinc is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 100 mg/100 kcal. More advantageously, the zinc can be present in the methods and/or compositions of the present invention in an amount of about 1 mg/100 kcal.
- manganese is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mg/100 kcal to about 10 mg/100 kcal. More advantageously, the manganese can be present in the methods and/or compositions of the present invention in an amount of about 0.16 mg/100 kcal.
- copper When copper is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 1 mg/100 kcal. More advantageously, the copper can be present in the methods and/or compositions of the present invention in an amount of about 80 mcg/100 kcal.
- iodine When iodine is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mcg/100 kcal to about 100 mcg/100 kcal. More advantageously, the iodine can be present in the methods and/or compositions of the present invention in an amount of about 12 mcg/100 kcal.
- selenium when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.01 mcg/100 kcal to about 1 mg/100 kcal. More advantageously, the selenium can be present in the methods and/or compositions of the present invention in an amount of about 3 mcg/100 kcal.
- sodium when sodium is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 500 mg/100 kcal. More advantageously, the sodium can be present in the methods and/or compositions of the present invention in an amount of between about 55 and 60 mg/100 kcal.
- potassium when potassium is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 1 g/100 kcal. More advantageously, the potassium can be present in the methods and/or compositions of the present invention in an amount of about 180 mg/100 kcal.
- chloride when present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 0.1 mg/100 kcal to about 1 g/100 kcal. More advantageously, the chloride can be present in the methods and/or compositions of the present invention in an amount of about 70 mg/100 kcal.
- the amount of sodium, potassium and chloride present in the nutritional supplements of the present invention may vary within a wide range based on the caloric content of the supplement.
- chromium When chromium is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 1 mcg/100 kcal to about 500 mcg/100 kcal.
- molybdenum When molybdenum is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 1 mcg/100 kcal to about 500 mcg/100 kcal.
- fluoride When fluoride is present in the methods and/or compositions of the present invention, it is advantageously present in a range of about 1 mg/100 kcal to about 500 mg/100 kcal.
- the amount of fiber can range from about 0.01 g/100 kcal to about 100 g/100 kcal. In other embodiments, the amount of fiber can range from about 0.1 g/100 kcal to about 10 g/100 kcal or the amount can range from about 0.5 g/100 kcal to about 1 g/100 kcaL In still other embodiments, the amount of fiber can be about 0.6 g/100 kcal.
- the nutritional supplement of the present invention may also contain one or more prebiotics.
- prebiotic means a non- digestible food ingredient that stimulates the growth and/or activity of probiotics.
- Prebiotics of the present invention may include lactulose, galacto-oligosaccharide. fructo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharides, lactosucrose, xylo-oligosacchairde, inulin, polydextrose and gentio-oligosaccharides.
- the nutritional supplement of the invention may also be administered to a subject in combination with human or animal milk (e.g., cow or goat milk).
- human or animal milk e.g., cow or goat milk.
- the liquid nutritional supplement contains about 250 kcal per serving. In other embodiments, the liquid nutritional supplement contains less than about 200 kcal per serving. In another embodiment, the liquid nutritional supplement contains between about 150 and 200 kcal per serving. In yet another embodiment, the liquid nutritional supplement contains between about 160 and 180 kcal per serving. In a further embodiment, the liquid nutritional supplement contains about 170 kcal per serving.
- the present invention is designed to deliver between about 7 and 20 mg/100 kcal DHA in a liquid nutritional supplement containing 250 kcal per serving.
- a liquid nutritional supplement containing 250 kcal per serving provides children between the ages of 1 and 10 with 2 to 4 servings of the supplement daily would result in from about 35 to about 200 mg supplemental DHA per day and would, therefore, address some of the gap between DHA intakes in this age group relative to the desired level of DHA consumption based on existing recommendations.
- the present invention is designed to deliver between about 7 and 75 mg/100 kcal DHA in a liquid nutritional supplement containing less than about 200 kcal per serving.
- the present invention is designed to deliver between 7 and 75 mg/100 kcal DHA in a liquid nutritional supplement containing between about 150 and 200 kcal per serving. In a particular embodiment, the present invention is designed to deliver between 7 and 75 mg/100 kcal DHA in a liquid nutritional supplement containing between about 160 and 180 kcal per serving. In another embodiment, the present invention is designed to deliver between 7 and 75 mg/100 kcal DHA in a liquid nutritional supplement containing about 170 kcal per serving.
- the liquid nutritional supplement contains less than about 200 kcal per serving and does not contain an artificial sweetener. In yet another embodiment, the liquid nutritional supplement contains between about 150 and 200 kcal per serving and does not contain an artificial sweetener. In yet another embodiment, the liquid nutritional supplement contains between about 160 and 180 kcal per serving and does not contain an artificial sweetener. In even another embodiment, the liquid nutritional supplement contains about 170 kcal per serving and does not contain an artificial sweetener. [000116]
- the nutritional supplement of the invention may be provided in any form suitable for administration to a subject.
- the nutritional supplement may be prepared in forms such as a liquid, powder, liquid/powder concentrate, ready-to-feed form, caplets, tablets, pills, capsules, puddings, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, solutions, suspensions, emulsions, multi-layer tablets, bi-layer tablets, soft gelatin capsules, hard gelatin capsules, lozenges, chewable lozenges, beads, granules, particles, microparticles, dispersible granules, cachets, implants, depot implants, ingestibles, injectables, infusions, health bars, cookies, confections, animal feeds, cereals, cereal coatings, foods, soups and soup concentrates, nutritive foods, functional foods, and combinations thereof.
- forms such as a liquid, powder, liquid/powder concentrate, ready-to-feed form, caplets, tablets, pills, capsules, puddings, chewable tablets, quick dissolve tablets, effervescent
- the nutritional supplement is provided in a liquid form.
- the preparation of the above dosage forms can be conducted as is known in the art.
- the nutritional supplements of this invention can be manufactured using techniques well known to those skilled in the art. For example, various processing techniques exist for producing powdered, ready-to-feed and liquid supplements.
- these techniques include formation of a slurry from one or more solutions which may contain water and one or more of the following: carbohydrates, proteins, lipids, stabilizers, vitamins and minerals.
- the pH of the slurry can be checked and, if required, adjusted to a relatively neutral pH, i.e., from about 6.5 to about 7.5 preferably about 7.0.
- the pH can be adjusted as required using any acid or base compatible with the present compositions, preferably citric acid, potassium hydroxide, or sodium phosphate dibasic.
- the liquid nutritional supplement is sterile.
- the supplement is aseptically sterilized and may be diluted to be utilized on a ready-to-feed basis or stored in a liquid or a powder. Homogenization and sterilization can be accomplished using standard equipment known to skilled artisans.
- the resulting nutritional supplement is meant to be a ready-to- feed liquid or concentrated liquid, an appropriate amount of water could be added before sterilization.
- the slurry will be heated and dried to obtain a powder. The powder resulting from drying may be dry blended with further ingredients, if desired.
- the nutritional supplement can be packaged for distribution and sale as desired using standard equipment known in the art. l
- Table 1 illustrates the ingredients present in an embodiment of the present liquid nutritional supplement and their amounts in grams (g) or milligrams (mg), expressed per Liter (L).
- Table 2 illustrates the amount of base nutrients (proteins, fats and carbohydrates), as well as vitamins and mineral nutrients present in 8 fl. oz. of an embodiment of the present liquid nutritional supplement.
- the caloric content in 8 fl. oz. of an embodiment of the present liquid nutritional supplement is approximately 250 kcal.
- Table 1 Ingredient Information and Concentrations (Per Liter)
- Table 3 illustrates the concentration of relevant components in the nutritional supplement of Example 1 expressed in grams per liter.
- This example illustrates another embodiment of the liquid nutritional supplement composition of the present invention.
- Table 6 illustrates the ingredients present in an embodiment of the present liquid nutritional supplement and their amounts expressed on a weight percentage of the total weight of the nutritional supplement.
- Table 7 illustrates the amount of base nutrients (proteins, fats and carbohydrates), as well as vitamins and mineral nutrients present in 8 fl. oz. of an embodiment of the present liquid nutritional supplement.
- the caloric content in 8 fl. oz. of an embodiment of the present liquid nutritional supplement is approximately 170 kcal.
- Table 8 illustrates the concentration of relevant components in the nutritional supplement of Example 2 expressed in grams per liter.
- This example illustrates a procedure for manufacturing an embodiment of the nutritional supplement of the present invention.
- the composition of an embodiment of the present invention can be found in the listing of components in Table 1.
- the protein source comprises a milk protein concentrate, which is a blend of casein and whey protein at a ratio of 8:2.
- the lipid source comprises a blend of the following based on w/w of the total lipid content: 29.3% canola oil, 20.7% soy oil, 20.5% high oleic sunflower oil, 19.8% medium chain triglyceride oil, 8.8% corn oil, and 0.9% DHA oil.
- the composition has a DHA content of about 17 mg/100 kcal.
- the carbohydrate source comprises a blend of maltodextrin and sucrose.
- the composition also comprises a suitable amount of carrageenan and a flavoring agent.
- the protein blend and the carbohydrate blend can be dispersed in water at room temperature with good mixing.
- the pH of the dispersion can then be adjusted to about 7 with potassium hydroxide.
- All vitamins and minerals can be dissolved in water, preheated at about 170 0 F, and the resulting solution can be added to the protein/carbohydrate dispersion.
- the pH can then be readjusted to about 7.
- the lipid blend can be preheated to about 160 0 F and then added to the carbohydrate/protein/vitamin and mineral suspension with good mixing. Any optional ingredients can also be added at this time. 6.
- the mixture can then be heated with direct steam injection to 225°F for 45 seconds, and then flash cooled to 160 0 F. 7.
- the mixture can then be homogenized twice using a two-stage homogenizer, at a total pressure of 3000 psig, with 2500 psig for the first stage and 500 psig for the second stage. 8.
- the mixture can then be aseptically sterilized at 268°F for 5 seconds at 2000 psig pressure and then packaged using a Dole Aseptic canning unit, Model 1305.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pediatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147001628A KR20140023443A (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
CA002633194A CA2633194A1 (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
CN2006800465619A CN101325882B (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
BRPI0619907-0A BRPI0619907A2 (en) | 2005-12-16 | 2006-12-14 | nutritional supplement containing long chain polyunsaturated fatty acids |
EP06848642A EP1959764A2 (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
KR1020087014334A KR101424822B1 (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
NO20081580A NO20081580L (en) | 2005-12-16 | 2008-04-01 | Nutritional supplements containing long-chain polyunsaturated fatty acids |
HK09105299.8A HK1132433A1 (en) | 2005-12-16 | 2009-06-12 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30337405A | 2005-12-16 | 2005-12-16 | |
US11/303,374 | 2005-12-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007070611A2 true WO2007070611A2 (en) | 2007-06-21 |
WO2007070611A3 WO2007070611A3 (en) | 2007-09-13 |
Family
ID=38163510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/047642 WO2007070611A2 (en) | 2005-12-16 | 2006-12-14 | Nutritional supplement containing long-chain polyunsaturated fatty acids |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070166411A1 (en) |
EP (1) | EP1959764A2 (en) |
KR (2) | KR101424822B1 (en) |
CN (1) | CN101325882B (en) |
BR (1) | BRPI0619907A2 (en) |
CA (1) | CA2633194A1 (en) |
HK (1) | HK1132433A1 (en) |
MY (1) | MY162133A (en) |
NO (1) | NO20081580L (en) |
RU (1) | RU2433749C2 (en) |
TW (1) | TWI452969B (en) |
WO (1) | WO2007070611A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008061512A2 (en) * | 2006-11-21 | 2008-05-29 | Ionescu John G | Dietetic foodstuff with an improved anti-inflammatory and free radical binding action |
EP2007215A2 (en) * | 2006-04-11 | 2008-12-31 | Martek Biosciences Corporation | Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same |
EP2076256A1 (en) * | 2006-10-03 | 2009-07-08 | Michael D. Myers | Meal replacement compositions and weight control method |
WO2011149713A2 (en) * | 2010-05-26 | 2011-12-01 | Morehouse School Of Medicine | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
EP2428217A1 (en) * | 2010-09-13 | 2012-03-14 | DMF Dietetic Metabolic Food S.R.L. | Composition based on docosahexaenoic acid (dha) for use in the treatment of cystic fibrosis and non-alcoholic hepatic steatosis |
RU2508121C2 (en) * | 2008-10-24 | 2014-02-27 | ЭмДжейЭн Ю.Эс. Холдингз ЭлЭлСи | Nutritional composition promoting normal development and growth |
US9968123B2 (en) | 2014-03-26 | 2018-05-15 | Abbott Laboratories | Nutritional supplement powder |
EP3771342A1 (en) * | 2019-07-31 | 2021-02-03 | Lactalis Puleva, S.L. | A drinkable dairy product for pregnant and lactating women |
US10912323B2 (en) | 2016-02-29 | 2021-02-09 | Abbott Laboratories | Nutritional supplement powder |
US11109607B2 (en) | 2013-11-18 | 2021-09-07 | Gary Hall | Oil-based compositions for enhancing oral health and general wellness in humans |
WO2021173096A3 (en) * | 2020-02-25 | 2022-02-17 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Nutritional compositions for promoting pediatric health maintenance |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6636833B1 (en) | 1998-03-25 | 2003-10-21 | Obis Patents Ltd. | Credit card system and method |
KR100903380B1 (en) * | 2008-11-04 | 2009-06-23 | 주식회사 일신웰스 | Fat composition |
CA2567879C (en) * | 2006-11-14 | 2013-03-26 | Thomas Greither | Nutritional food oil compositions and methods of making same |
US20080206430A1 (en) * | 2007-02-22 | 2008-08-28 | Rafael Avila | Compositions consisting of blended vegetarian proteins |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
US20110177224A1 (en) * | 2008-03-03 | 2011-07-21 | Daniel Perlman | Stabilization of omega-3 fatty acids in oil-water emulsions |
EP2268274B1 (en) | 2008-03-20 | 2012-05-16 | Virun, Inc. | Vitamin e derivatives and their uses |
EP2268160B1 (en) | 2008-03-20 | 2012-12-05 | Virun, Inc. | Emulsions including a peg-derivative of tocopherol |
WO2009126932A2 (en) * | 2008-04-10 | 2009-10-15 | Provide Nutrition | Fortified liquid protein compositions and methods of making same |
CN102131407B (en) * | 2008-06-23 | 2015-01-07 | 维尔恩公司 | Compositions containing nono-polar compounds |
US9655919B2 (en) | 2008-07-09 | 2017-05-23 | The General Hospital Corporation | Methods and compositions for bowel cleansing before a medical procedure |
US20100077654A1 (en) * | 2008-09-23 | 2010-04-01 | LiveFuels, Inc. | Systems and methods for producing biofuels from algae |
PT2374452T (en) * | 2008-12-05 | 2019-10-31 | Ajinomoto Kk | Nutrient composition |
PL2429317T5 (en) * | 2009-04-17 | 2019-09-30 | Natac Pharma, S.L. | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
WO2010121094A1 (en) * | 2009-04-17 | 2010-10-21 | Livefuels. Inc. | Systems and methods for culturing algae with bivalves |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
EP2279667A1 (en) | 2009-07-30 | 2011-02-02 | Brudy Technology, S.L. | Vegetable and marine oil or fat compositions enriched with DHA or EPA and C18 or higher fatty acid |
US20110044964A1 (en) * | 2009-08-24 | 2011-02-24 | Hero Nutritionals, LLC | Plant-based omega chewable supplement |
CN102917702A (en) * | 2009-09-23 | 2013-02-06 | 夏威夷大学 | Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins |
US20110135753A1 (en) * | 2009-12-04 | 2011-06-09 | John Wigneswaran | Nutritional Supplement For Patients With Chronic Heart Failure |
CN103037708B (en) * | 2010-03-23 | 2015-05-20 | 维尔恩公司 | Nanoemulsion including sucrose fatty acid ester |
US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
EP2592938B1 (en) * | 2010-07-16 | 2021-11-24 | Fonterra Co-Operative Group Limited | Dairy product and process |
RU2013140443A (en) * | 2011-02-02 | 2015-03-10 | Нестек С.А. | NUTRITIONAL COMPOSITIONS WITH A HIGH PROTEIN CONTENT AND METHODS OF PREPARING AND USING THEM |
US20120269929A1 (en) * | 2011-04-22 | 2012-10-25 | Hugh Lippman | Fortified Milk-Based Nutritional Compositions |
US9487716B2 (en) | 2011-05-06 | 2016-11-08 | LiveFuels, Inc. | Sourcing phosphorus and other nutrients from the ocean via ocean thermal energy conversion systems |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
RU2483712C2 (en) * | 2011-07-25 | 2013-06-10 | Еврофарм (ЮК) Ко. Лтд | Pharmaceutical composition possessing hepatoprotecting, hypolipidemic, immunostimulating and normalising kidney function action, and method of its obtaining |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
MY170185A (en) * | 2011-10-18 | 2019-07-09 | Nestle Sa | Composition for use in brain growth and/or cognitive and/or psychomotor development |
FR2981544B1 (en) * | 2011-10-25 | 2014-01-31 | Internat Nutrition Res Company | DIETETIC PRODUCT FOR PREVENTING CARDIOMETABOLIC RISK |
SG11201404640YA (en) | 2012-02-10 | 2014-09-26 | Virun Inc | Beverage compositions containing non-polar compounds |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
US9345741B2 (en) * | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
WO2014151109A1 (en) | 2013-03-15 | 2014-09-25 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin e and compositions containing same |
US9693574B2 (en) | 2013-08-08 | 2017-07-04 | Virun, Inc. | Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch |
US8932647B1 (en) * | 2013-08-11 | 2015-01-13 | Matthew F. Taylor, Jr. | Functional beverage composition |
CN104026591A (en) * | 2014-04-04 | 2014-09-10 | 上海英莱腾医药研究有限公司 | Multifunctional protein food composition containing medium chain triglyceride |
AU2015253178B2 (en) | 2014-04-29 | 2020-03-12 | Colonaryconcepts Llc | Foods, systems, methods, and kits for providing electrolyte replacement |
WO2015191639A1 (en) | 2014-06-10 | 2015-12-17 | Alatalab Solutions, Llc | Methods and compositions for treating and/or inhibiting toxins using copper-containing compounds |
CA2958076A1 (en) | 2014-08-14 | 2016-02-18 | Change Cola, Inc. | Carbonated drink comprising omega, vitamins and minerals |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
WO2016044805A1 (en) | 2014-09-18 | 2016-03-24 | Virun, Inc. | Soft gel compositions and pre-gel concentrates |
US10016363B2 (en) | 2014-09-18 | 2018-07-10 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
US9446100B2 (en) | 2015-02-13 | 2016-09-20 | Eastern Vision Limited | Dietary supplements and formulations |
WO2018210788A1 (en) | 2017-05-18 | 2018-11-22 | Firmenich Sa | Marine protein hydrolysate compositions with reduced malodor |
KR102055983B1 (en) * | 2017-11-10 | 2019-12-13 | 김양희 | The Mixture for manufacturing of companion animal feeds having in blood sugar level |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
CN111526737A (en) * | 2017-12-28 | 2020-08-11 | 雀巢产品有限公司 | Composition comprising ferrous sulfate monohydrate and long chain polyunsaturated fatty acids |
CN111067876B (en) * | 2019-12-04 | 2022-08-16 | 宁夏大学 | Alpha-linolenic acid double-layer tablet and preparation method thereof |
CA3168636A1 (en) * | 2020-01-30 | 2021-08-05 | Silicycle Inc. | Process of producing magnesium salts of pufas and composition containing same |
KR20230010404A (en) * | 2021-07-12 | 2023-01-19 | 에이치케이이노엔 주식회사 | Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same |
CN114009786B (en) * | 2021-11-22 | 2023-04-07 | 江南大学 | Nutritional oil composition for vitamin D delivery, preparation method and application |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4304394A1 (en) * | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
US5374657A (en) * | 1991-01-24 | 1994-12-20 | Martek Corporation | Microbial oil mixtures and uses thereof |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
WO2002015720A2 (en) * | 2000-08-22 | 2002-02-28 | Société des Produits Nestlé S. A. | Nutritional composition an method for improving protein deposition |
WO2003043445A2 (en) * | 2001-11-21 | 2003-05-30 | Gerber Products Company | Processed baby food with unsaturated fatty acids and/or nucleotides |
US20040013787A1 (en) * | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
WO2004105516A1 (en) * | 2003-05-28 | 2004-12-09 | Nutrinova | Dietary food items for a weight control or weight loss diet |
WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
US20050054724A1 (en) * | 2003-09-05 | 2005-03-10 | Mustad Vikkie A. | Lipid system and methods of use |
EP1557096A1 (en) * | 1999-12-13 | 2005-07-27 | N.V. Nutricia | Infant formula with improved fat composition |
WO2005084129A2 (en) * | 2004-03-04 | 2005-09-15 | Htl High-Tech Lipids Ltd. | Structured triglycerides and emulsions comprising same |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670285A (en) * | 1982-08-06 | 1987-06-02 | The University Of Toronto Innovations Foundation | Infant formula |
GB8317248D0 (en) * | 1983-06-24 | 1983-07-27 | Wyeth John & Brother Ltd | Fat compositions |
US5197468A (en) * | 1990-02-13 | 1993-03-30 | Proctor Paul W | Device for protecting an electronic prosthesis from adverse effects of RF and/or electrostatic energy |
US5013569A (en) * | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
US5169666A (en) * | 1991-11-14 | 1992-12-08 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of simulated human milk protein by low temperature microfiltration |
US5234702A (en) * | 1992-03-19 | 1993-08-10 | Abbott Laboratories | Antioxidant system for powdered nutritional products |
US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5422127A (en) * | 1992-12-21 | 1995-06-06 | Bristol-Myers Squibb Company | Nutritional compositions containing vitamin D esters |
US5480872A (en) * | 1993-05-28 | 1996-01-02 | Abbott Laboratories | Method of providing enternal nutritional support to persons infected with human immunodeficiency virus |
US5330972A (en) * | 1993-05-28 | 1994-07-19 | Abbott Laboratories | Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus |
US5403826A (en) * | 1993-05-28 | 1995-04-04 | Abbott Laboratories | Nutritional product for persons infected with human immunodeficiency virus |
US6136858A (en) * | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
CA2150741A1 (en) * | 1994-06-17 | 1995-12-18 | Susan Trimbo | Pediatric lipid emulsion |
FR2721481B1 (en) * | 1994-06-27 | 1996-09-06 | Inst Rech Biolog Sa | New dietary compositions based on phospholipids and their use as a nutritional supplement. |
US5686491A (en) * | 1994-09-14 | 1997-11-11 | Sigma-Tau Pharmaceuticals, Inc. | Infant formula |
US5549905A (en) * | 1994-10-18 | 1996-08-27 | Clintec Nutrition Co. | Enternal composition for pediatric patients |
GB9510636D0 (en) * | 1995-05-25 | 1995-07-19 | Scotia Holdings Plc | Fatty acid treatment |
US5635199A (en) * | 1995-10-27 | 1997-06-03 | Nestec Ltd. | Support of pediatric patients |
US6200624B1 (en) * | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
GB9617847D0 (en) * | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
US6428990B1 (en) * | 1997-04-11 | 2002-08-06 | Abbott Laboratories | Human desaturase gene and uses thereof |
US6432684B1 (en) * | 1997-04-11 | 2002-08-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
US6297279B1 (en) * | 1997-07-22 | 2001-10-02 | Nestac S.A. | Lipid composition for infant formula and method of preparation |
WO1999006585A1 (en) * | 1997-08-01 | 1999-02-11 | Martek Biosciences Corporation | Dha-containing nutritional compositions and methods for their production |
US6294206B1 (en) * | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
US7112609B2 (en) * | 1999-06-01 | 2006-09-26 | Drugtech Corporation | Nutritional supplements |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6596302B2 (en) * | 2000-04-13 | 2003-07-22 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
US6576253B2 (en) * | 2000-12-05 | 2003-06-10 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
US6569445B2 (en) * | 2000-12-05 | 2003-05-27 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity maintaining-agents |
GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
US20030000391A1 (en) * | 2001-06-12 | 2003-01-02 | Jay Highman | Organic nutritional formula |
AU2002323409A1 (en) * | 2001-08-24 | 2003-03-10 | Martek Biosciences Boulder Corporation | Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum |
US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
DE20119176U1 (en) * | 2001-11-24 | 2002-07-11 | SAMADHI BIOCYBERNETICS GmbH, 50374 Erftstadt | Dietetic food |
US6923995B2 (en) * | 2002-03-27 | 2005-08-02 | Jay C. Highman | Rice protein concentrate based organic nutritional formula |
US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
SE526943C2 (en) * | 2002-08-26 | 2005-11-22 | Indevex Ab | food composition |
US6860756B2 (en) * | 2003-01-14 | 2005-03-01 | Uta Auto Industrial Co., Ltd. | Terminal with a heat shrink collar for wrapping connected wires |
US6753350B1 (en) * | 2003-03-24 | 2004-06-22 | Bristol-Myers Squibb Company | Method to reduce the incidence of intraventricular hemorrhage in preterm infants |
WO2004112507A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
CN1842277A (en) * | 2003-06-24 | 2006-10-04 | 堪萨斯大学医学中心 | Infant formula |
US20050202063A1 (en) * | 2003-08-26 | 2005-09-15 | Ebn International Kft | Food product |
CN1293816C (en) * | 2005-04-21 | 2007-01-10 | 石家庄三鹿集团股份有限公司 | Pregnant woman benefiting milk powder |
-
2006
- 2006-12-11 US US11/637,484 patent/US20070166411A1/en not_active Abandoned
- 2006-12-14 TW TW095146911A patent/TWI452969B/en not_active IP Right Cessation
- 2006-12-14 CN CN2006800465619A patent/CN101325882B/en active Active
- 2006-12-14 CA CA002633194A patent/CA2633194A1/en not_active Abandoned
- 2006-12-14 RU RU2008119280/13A patent/RU2433749C2/en not_active IP Right Cessation
- 2006-12-14 MY MYPI20081602A patent/MY162133A/en unknown
- 2006-12-14 KR KR1020087014334A patent/KR101424822B1/en not_active IP Right Cessation
- 2006-12-14 EP EP06848642A patent/EP1959764A2/en not_active Withdrawn
- 2006-12-14 BR BRPI0619907-0A patent/BRPI0619907A2/en not_active IP Right Cessation
- 2006-12-14 WO PCT/US2006/047642 patent/WO2007070611A2/en active Application Filing
- 2006-12-14 KR KR1020147001628A patent/KR20140023443A/en not_active Application Discontinuation
-
2008
- 2008-04-01 NO NO20081580A patent/NO20081580L/en not_active Application Discontinuation
-
2009
- 2009-06-12 HK HK09105299.8A patent/HK1132433A1/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374657A (en) * | 1991-01-24 | 1994-12-20 | Martek Corporation | Microbial oil mixtures and uses thereof |
DE4304394A1 (en) * | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
EP1557096A1 (en) * | 1999-12-13 | 2005-07-27 | N.V. Nutricia | Infant formula with improved fat composition |
WO2002015720A2 (en) * | 2000-08-22 | 2002-02-28 | Société des Produits Nestlé S. A. | Nutritional composition an method for improving protein deposition |
WO2003043445A2 (en) * | 2001-11-21 | 2003-05-30 | Gerber Products Company | Processed baby food with unsaturated fatty acids and/or nucleotides |
US20040013787A1 (en) * | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
WO2004105516A1 (en) * | 2003-05-28 | 2004-12-09 | Nutrinova | Dietary food items for a weight control or weight loss diet |
WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
US20050054724A1 (en) * | 2003-09-05 | 2005-03-10 | Mustad Vikkie A. | Lipid system and methods of use |
WO2005084129A2 (en) * | 2004-03-04 | 2005-09-15 | Htl High-Tech Lipids Ltd. | Structured triglycerides and emulsions comprising same |
Non-Patent Citations (5)
Title |
---|
JENSEN R G: "LIPIDS IN HUMAN MILK" LIPIDS, CHAMPAIGN, IL, US, vol. 34, no. 12, 1999, pages 1243-1271, XP008040614 ISSN: 0024-4201 * |
KOCH T ET AL: "Benefits of omega-3 fatty acids in parenteral nutrition" CLINICAL NUTRITION SUPPLEMENTS, ELSEVIER, vol. 1, no. 3, 2005, pages 17-24, XP004988204 ISSN: 1744-1161 * |
KOLETZKO B ET AL: "EFFECTS OF DIETARY LONG-CHAIN POLYUNSATURATED FATTY ACIDS ON THE ESSENTIAL FATTY ACID STATUS OF PREMATURE INFANTS" EUROPEAN JOURNAL OF PEDIATRICS, SPRINGER VERLAG, vol. 148, no. 7, 1989, pages 669-675, XP009046783 ISSN: 0340-6199 * |
MORLION B J ET AL: "P.98 What is the optimum omega-3 to omega-6 fatty acid (FA) ratioof parenteral lipid emulsions in postoperative trauma?" CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 16, August 1997 (1997-08), page 49, XP004683442 ISSN: 0261-5614 * |
SIMOPOULOS A P: "The importance of the ratio of omega-6/omega-3 essential fatty acids" BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, PARIS, FR, vol. 56, no. 8, October 2002 (2002-10), pages 365-379, XP002438414 ISSN: 0753-3322 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2007215A2 (en) * | 2006-04-11 | 2008-12-31 | Martek Biosciences Corporation | Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same |
EP2007215A4 (en) * | 2006-04-11 | 2011-04-13 | Martek Biosciences Corp | Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same |
EP2076256A1 (en) * | 2006-10-03 | 2009-07-08 | Michael D. Myers | Meal replacement compositions and weight control method |
EP2076256A4 (en) * | 2006-10-03 | 2010-01-13 | Michael Myers | Meal replacement compositions and weight control method |
US9066915B2 (en) | 2006-10-03 | 2015-06-30 | Michael D. Myers | Meal replacement compositions and weight control method |
WO2008061512A3 (en) * | 2006-11-21 | 2008-09-18 | John G Ionescu | Dietetic foodstuff with an improved anti-inflammatory and free radical binding action |
WO2008061512A2 (en) * | 2006-11-21 | 2008-05-29 | Ionescu John G | Dietetic foodstuff with an improved anti-inflammatory and free radical binding action |
RU2508121C2 (en) * | 2008-10-24 | 2014-02-27 | ЭмДжейЭн Ю.Эс. Холдингз ЭлЭлСи | Nutritional composition promoting normal development and growth |
US8840950B2 (en) | 2010-05-26 | 2014-09-23 | Jacqueline M. Hibbert | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
WO2011149713A3 (en) * | 2010-05-26 | 2012-03-01 | Morehouse School Of Medicine | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
WO2011149713A2 (en) * | 2010-05-26 | 2011-12-01 | Morehouse School Of Medicine | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
US9375451B2 (en) | 2010-05-26 | 2016-06-28 | Nutriglobal, Inc. | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
US11058719B2 (en) | 2010-05-26 | 2021-07-13 | Morehouse School Of Medicine | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
EP2428217A1 (en) * | 2010-09-13 | 2012-03-14 | DMF Dietetic Metabolic Food S.R.L. | Composition based on docosahexaenoic acid (dha) for use in the treatment of cystic fibrosis and non-alcoholic hepatic steatosis |
US11109607B2 (en) | 2013-11-18 | 2021-09-07 | Gary Hall | Oil-based compositions for enhancing oral health and general wellness in humans |
US9968123B2 (en) | 2014-03-26 | 2018-05-15 | Abbott Laboratories | Nutritional supplement powder |
US10595553B2 (en) | 2014-03-26 | 2020-03-24 | Abbott Laboratories | Nutritional supplement powder |
US10912323B2 (en) | 2016-02-29 | 2021-02-09 | Abbott Laboratories | Nutritional supplement powder |
EP3771342A1 (en) * | 2019-07-31 | 2021-02-03 | Lactalis Puleva, S.L. | A drinkable dairy product for pregnant and lactating women |
WO2021018878A1 (en) * | 2019-07-31 | 2021-02-04 | Lactalis Puleva, S.L. | A drinkable dairy product for pregnant and lactating women |
WO2021173096A3 (en) * | 2020-02-25 | 2022-02-17 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Nutritional compositions for promoting pediatric health maintenance |
Also Published As
Publication number | Publication date |
---|---|
TWI452969B (en) | 2014-09-21 |
WO2007070611A3 (en) | 2007-09-13 |
CN101325882B (en) | 2012-09-05 |
KR20140023443A (en) | 2014-02-26 |
KR20080080988A (en) | 2008-09-05 |
CN101325882A (en) | 2008-12-17 |
TW200744463A (en) | 2007-12-16 |
EP1959764A2 (en) | 2008-08-27 |
CA2633194A1 (en) | 2007-06-21 |
KR101424822B1 (en) | 2014-08-01 |
BRPI0619907A2 (en) | 2011-10-25 |
RU2008119280A (en) | 2010-02-10 |
HK1132433A1 (en) | 2010-02-26 |
MY162133A (en) | 2017-05-31 |
RU2433749C2 (en) | 2011-11-20 |
US20070166411A1 (en) | 2007-07-19 |
NO20081580L (en) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070166411A1 (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
RU2409388C1 (en) | Supporting continuous enteral feeding | |
CN105025734A (en) | Nutritional compositions containing an enriched lipid fraction and uses thereof | |
JP6096571B2 (en) | Long-term nutrition supply for the elderly | |
US9457058B2 (en) | Nutritional composition containing a peptide component with anti-inflammatory properties and uses thereof | |
US8277854B2 (en) | Nutritional compositions containing punicalagins | |
TW201729693A (en) | Nutritional compositions containing dietary butyrate and uses thereof | |
AU2014260349B2 (en) | Nutritional composition comprising whey and hydrolyzed casein and uses thereof | |
CA3140001A1 (en) | Nutritional compositions | |
US20160353774A1 (en) | Nutritional compositions comprising spore-forming probiotics | |
MX2008007189A (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
JP2001231496A (en) | Nutritive composition | |
Gonzalez et al. | THAT ARE NOT OULUULUTUTE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680046561.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008500862 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3430/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/007189 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006848642 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2633194 Country of ref document: CA Ref document number: 1020087014334 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008119280 Country of ref document: RU |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: PI0619907 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080617 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147001628 Country of ref document: KR |